Forbion raises new fund to top up existing investments
This article was originally published in Clinica
Executive Summary
Forbion Capital Partners has conducted the "first and final" closing of its second FCF 1 Co-Investment Fund at around $50m. The fund will invest additional capital in several "pre-defined" late-stage FCF 1 portfolio companies that are close to exit, Sander Slootweg, managing partner at Forbion, told Clinica.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.